Cargando…
Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and endocrine therapy are the gold standards for systemic therapy for patients with hormone-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer. Following progression, no prospective randomized data exi...
Autores principales: | Stanciu, Ioana-Miruna, Pirlog, Cristina Florina, Anghel, Andrei-Wilhelm, Parosanu, Andreea Ioana, Olaru, Cristina Mihaela, Orlov-Slavu, Cristina, Iaciu, Ion Cristian, Popa, Ana Maria, Vrabie, Radu Constantin, Nitipir, Cornelia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145154/ https://www.ncbi.nlm.nih.gov/pubmed/37109654 http://dx.doi.org/10.3390/medicina59040696 |
Ejemplares similares
-
Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
por: Stanciu, Ioana-Miruna, et al.
Publicado: (2023) -
Infection and reinfection with SARS-CoV-2 in cancer patients: A cohort study
por: Nitipir, Cornelia, et al.
Publicado: (2022) -
Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy
por: Parosanu, Andreea, et al.
Publicado: (2022) -
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Patients with Metastatic Renal Cell Carcinoma
por: Parosanu, Andreea Ioana, et al.
Publicado: (2023) -
Use of Immune Checkpoint Inhibitors in Elderly Patients With Chronic Kidney Disease and Renal Cell Carcinoma Metastasis of the Parotid Gland: Case Report and Review of the Literature
por: Parosanu, Andreea, et al.
Publicado: (2022)